Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of cancer
cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop
tumor cells from dividing so they stop growing or die. Combining gefitinib with chemotherapy
may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combining gefitinib with temozolomide in
treating patients who have malignant primary glioma.
Phase:
Phase 1
Details
Lead Sponsor:
North American Brain Tumor Consortium Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins